Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 114972253 | 11497225 | 3 | F | 20150117 | 20160831 | 20150911 | 20160909 | EXP | US-PFIZER INC-2015297305 | PFIZER | 14.00 | YR | F | Y | 56.00000 | KG | 20160909 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 114972253 | 11497225 | 1 | PS | CRIZOTINIB | CRIZOTINIB | 1 | Oral | COURSE A, B: 165 MG/M2, CYCLIC TWICE DAILY ON DAYS 1-21 | 33990 | MG/M2 | Y | 202570 | 165 | MG/M**2 | |||||
| 114972253 | 11497225 | 2 | SS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Intrathecal | PROPHASE: 7.5-12MG INTRATHECAL (IT) ON DAY 1 (AGE BASED DOSING) | Y | 11719 | |||||||||
| 114972253 | 11497225 | 3 | SS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Intravenous (not otherwise specified) | COURSE A, B: 3000 MG/M2, CYCLIC (OVER 3 HOURS ON DAY 1) | Y | 11719 | 3000 | MG/M**2 | |||||||
| 114972253 | 11497225 | 4 | SS | CYTARABINE. | CYTARABINE | 1 | Intrathecal | PROPHASE: 15-24 MG ON DAY 1 (AGE BASED DOSING) | Y | 71868 | |||||||||
| 114972253 | 11497225 | 5 | SS | CYTARABINE. | CYTARABINE | 1 | Intravenous (not otherwise specified) | COURSE A: 150 MG/M2, CYCLIC OVER 1-30 MINUTES EVERY 12 HOURS ON DAYS 4 AND 5 (TOTAL 4 DOSES) | Y | 71868 | 150 | MG/M**2 | |||||||
| 114972253 | 11497225 | 6 | SS | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | PROPHASE: 5MG/M2 ORAL (PO) ONCE DAILY (QD) ON DAYS 1-2, AND 5MG/M2 PO TWICE DAILY (BID) ON DAYS 3-5 | 82 | MG | Y | 0 | 5 | MG/M**2 | |||||
| 114972253 | 11497225 | 7 | SS | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | COURSE A, B: 5 MG, CYCLIC (TWICE DAILY ON DAYS 1-5) | 82 | MG | Y | 0 | 5 | MG | |||||
| 114972253 | 11497225 | 8 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | Intravenous (not otherwise specified) | COURSE A: 100 MG/M2, CYCLIC (OVER 2 HOURS ON DAYS 4 AND 5) | Y | 0 | 100 | MG/M**2 | |||||||
| 114972253 | 11497225 | 9 | SS | IFOSFAMIDE. | IFOSFAMIDE | 1 | Intravenous (not otherwise specified) | COURSE A: 800 MG/M2, CYCLIC (OVER 60 MIN ON DAYS 1-5) | Y | 0 | 800 | MG/M**2 | |||||||
| 114972253 | 11497225 | 10 | C | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | Intravenous (not otherwise specified) | PROPHASE: 200MG/M2 INTRAVENOUS (IV) OVER 15-30 MINUTES ON DAYS 1 AND 2 | 0 | 200 | MG/M**2 | ||||||||
| 114972253 | 11497225 | 11 | C | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | Intravenous (not otherwise specified) | COURSE B: 200 MG/M2, CYCLIC ( OVER 15-30 MINUTES ON DAYS 1 AND 2) | 0 | 200 | MG/M**2 | ||||||||
| 114972253 | 11497225 | 12 | C | HYDROCORTISONE. | HYDROCORTISONE | 1 | Intrathecal | PROPHASE: 7.5-12MG, ON DAY 1 | 0 | ||||||||||
| 114972253 | 11497225 | 13 | C | DOXORUBICIN HYDROCHLORIDE. | DOXORUBICIN HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | COURSE B: 25 MG/M2, CYCLIC (OVER 1-15 MIN ON DAYS 4 AND 5) | 0 | 25 | MG/M**2 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 114972253 | 11497225 | 1 | Anaplastic large cell lymphoma T- and null-cell types |
| 114972253 | 11497225 | 2 | Anaplastic large cell lymphoma T- and null-cell types |
| 114972253 | 11497225 | 4 | Anaplastic large cell lymphoma T- and null-cell types |
| 114972253 | 11497225 | 6 | Anaplastic large cell lymphoma T- and null-cell types |
| 114972253 | 11497225 | 8 | Anaplastic large cell lymphoma T- and null-cell types |
| 114972253 | 11497225 | 9 | Anaplastic large cell lymphoma T- and null-cell types |
| 114972253 | 11497225 | 10 | Anaplastic large cell lymphoma T- and null-cell types |
| 114972253 | 11497225 | 12 | Anaplastic large cell lymphoma T- and null-cell types |
| 114972253 | 11497225 | 13 | Anaplastic large cell lymphoma T- and null-cell types |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 114972253 | 11497225 | HO |
| 114972253 | 11497225 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 114972253 | 11497225 | Pyrexia | |
| 114972253 | 11497225 | White blood cell count decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 114972253 | 11497225 | 1 | 20141007 | 20150121 | 0 | |
| 114972253 | 11497225 | 3 | 20141007 | 20150108 | 0 | |
| 114972253 | 11497225 | 5 | 20141010 | 20150112 | 0 | |
| 114972253 | 11497225 | 7 | 20141007 | 20150112 | 0 | |
| 114972253 | 11497225 | 8 | 20141010 | 20150112 | 0 | |
| 114972253 | 11497225 | 9 | 20141007 | 20150111 | 0 | |
| 114972253 | 11497225 | 11 | 20141220 | 0 | ||
| 114972253 | 11497225 | 13 | 20141220 | 0 |